A Closer Look at Spravato (Esketamine)
Topic: What will the drug cost and will insurance cover it?
As the P.R. machine kicks into gear to support the launch of Spravato/Esketamine, the first FDA approved Ketamine-derived treatment, Kevin Nicholson (President, CEO of Ketamine Wellness Centers) digs into the details that tend to receive less attention.
Wholesale estimates are between $580 – $885 per treatment (depending on dose). At a recommended schedule of two treatments over four weeks, we’re looking at a monthly range of $4700 – $7080 towards the first month of treatment. This episode focuses on the cost of Spravato to the provide, end user, and insurer.
- What are the preliminary cost estimates for Spravato (wholesale)?
- Can we estimate the cost to the patient?
- Will insurance cover the drug?
- How will the treatment schedule effect the cost?
Our experienced team of physicians, nurse practitioners, and research staff break down each topic in short, to-the-point podcasts, which you may listen to on your own time by subscribing to Ketamine Wellness Centers on iTunes or tune in by following the KWC blog.